FDA will expedite review of cancer drug Istodax for expanded use

02/28/2011 | Reuters

The FDA granted priority-review status to Celgene's Istodax for use in patients with peripheral T-cell lymphoma who have undergone prior treatment. The agency, which approved the drug for cutaneous T-cell lymphoma, is expected to decide by June 17 on the expanded use.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC